NVO: Novo Nordisk Inc. Price-to-Revenue Multiple

Brandmark of Novo Nordisk Inc. (NVO)

Can the hype surrounding Wegovy and Ozempic drive further growth in share prices for Novo Nordisk A/S (NVO)? The answer lies in the expansion of production facilities and a strategic focus on rare pathologies. A stable team of experts supports these ambitions, as evidenced by the shift in the P/S multiple. The current value is 2.60, reflecting the present balance between market pressure and capitalization relative to the company's revenue.

NVO (Novo Nordisk Inc.) Price-to-Revenue Ratio history from 07/04/2022 to 11/18/2026

Metric breakdowns and analytics for Novo Nordisk AS (NVO)

- stock price and consensus target price:
Summary company analytics:Novo Nordisk AS, NVO
Product sample of Novo Nordisk

As a global leader in diabetes therapy, Novo Nordisk A/S (NVO) is subject to the influence of cross-border trade barriers and logistical disruptions that limit access to biopharmaceutical markets. By analyzing price-to-sales dynamics, an investor assesses market capitalization relative to revenue, which allows them to filter out price volatility and determine the fair value of the business, avoiding overpaying for the asset amid geopolitical uncertainty.